Literature DB >> 6717922

5-fluorouracil and glaucoma filtering surgery: I. An animal model.

M G Gressel, R K Parrish, R Folberg.   

Abstract

Failure of a glaucoma filtering procedure commonly results from scarring at the surgical site. Fibroblasts play an important role in the scarring process. 5-fluorouracil is an antimetabolite capable of inhibiting fibroblast proliferation. We tested the ability of 5-fluorouracil to inhibit cicatrization at the filtering site in an experimental model. Posterior lip sclerectomies were performed in each eye of ten normal owl monkeys. Postoperatively, one eye of each animal received subconjunctival injections of fluorouracil and the fellow eye received saline injections in a randomized, masked fashion. Two animals died of undetermined causes. None of the control eyes developed blebs, but six of the eight treated eyes in surviving animals developed blebs. The difference between intraocular pressures in fluorouracil-treated and control eyes was statistically significant (P less than 0.05). Signs of ocular toxicity included persistent corneal epithelial defects and delayed healing of the conjunctival incision. These results are considerably more favorable than those previously reported with experimental filtering procedures in non-human primates. Pharmacologic modulation of wound healing may decrease the risk of failure of filtering operations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6717922     DOI: 10.1016/s0161-6420(84)34277-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  29 in total

1.  Biodegradable tube implants in experimental glaucoma surgery in the rabbit.

Authors:  M Kivalo; V Siren; C Raitta; I Immonen
Journal:  J Mater Sci Mater Med       Date:  1999-01       Impact factor: 3.896

2.  Trypan blue identifies antimetabolite treatment area in trabeculectomy.

Authors:  P R Healey; J G Crowston
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

3.  Collagen type I and III synthesis by Tenon's capsule fibroblasts in culture: individual patient characteristics and response to mitomycin C, 5-fluorouracil, and ascorbic acid.

Authors:  R L Gross
Journal:  Trans Am Ophthalmol Soc       Date:  1999

4.  New model of conjunctival scarring in the mouse eye.

Authors:  M B Reichel; M F Cordeiro; R A Alexander; I A Cree; S S Bhattacharya; P T Khaw
Journal:  Br J Ophthalmol       Date:  1998-09       Impact factor: 4.638

5.  The use of a liposome-encapsulated 5-fluoroorotate for glaucoma surgery: I. Animal studies.

Authors:  J A Alvarado
Journal:  Trans Am Ophthalmol Soc       Date:  1989

6.  Identification and Correction of Restrictive Strabismus After Pterygium Excision Surgery.

Authors:  Sally L Baxter; Brian J Nguyen; Michael Kinori; Don O Kikkawa; Shira L Robbins; David B Granet
Journal:  Am J Ophthalmol       Date:  2019-02-14       Impact factor: 5.258

7.  Dose, timing and frequency of subconjunctival 5-fluorouracil injections after glaucoma filtering surgery.

Authors:  Eva Kristina Reinthal; Paul Oliver Denk; Matthias Grüb; Dorothea Besch; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-17       Impact factor: 3.117

8.  Effect of fibrostatin C, an inhibitor of prolyl 4-hydroxylase, on collagen secretion by human Tenon's capsule fibroblasts in vitro.

Authors:  S Saika; A Ooshima; O Yamanaka; Y Okada; S Tanaka; Y Ohnishi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

9.  In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(D,L-lactide-co-glycolide).

Authors:  G Wang; I G Tucker; M S Roberts; L W Hirst
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

10.  Efficacy and safety of trabeculectomy with mitomycin C for childhood glaucoma: a study of results with long-term follow-up.

Authors:  Jair Giampani; Adriana Silva Borges-Giampani; José Carlos Eudes Carani; Ernst Werner Oltrogge; Remo Susanna
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.